Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

cus on and commitment to patient communities."

Takeda submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in June, 2013, as well as a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in March, 2013, seeking approval for vedolizumab for the treatment of adults with moderately to severely active CD and UC.

CD and UC are chronic diseases of the digestive tract. CD can involve all areas of the digestive tract, while UC typically affects the colon and rectum. CD and UC can be both painful and debilitating and patients may have bleeding, diarrhea, fatigue, weight loss and anemia, among other symptoms. Both diseases involve excess inflammation in the gut tissue that occurs when white blood cells infiltrate the gastrointestinal tract and may lead to serious complications. 

"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis"
The publication, titled "Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis," discusses findings from GEMINI I, a Phase 3, randomized, double-blind, placebo-controlled induction and maintenance study designed to assess the efficacy and safety of vedolizumab on clinical response and remission in patients with moderately to severely active UC, in whom one prior therapy had failed. In the induction phase, the primary endpoint was improvement in clinical response at six weeks. Secondary endpoints were to determine the effect of vedolizumab induction treatment on clinical remission and mucosal healing at six weeks. The intent-to-treat (ITT) population comprised 374 patients, with an additional 521 patients receiving open-label vedolizumab. Of the 374, 225 received vedolizumab 300 mg IV and 149 received placebo on days 1 and 15. Approximately 40 percent of the ITT population had prior anti-TNF failure. At week six, 47.1 percent of patients receiving vedolizumab achieved clinical response compared to 2
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., ... information systems technology, will feature an exhibit booth during ... Meeting and Clinical Lab Expo in ... "We are extremely excited to exhibit ... to interact with our customers and continue the dialogue ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation (Apex, ... Pressure Area Care sectors, announces that it is appealing the ... in Germany that found the ... notes that it has initiated invalidity challenges against various ResMed ... in counterattacking against trivial and junk patents. ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory ... that it is a Bronze winner in the 35th Annual ... Through a Child's Eye and Silverado Resident Visits ... a Child's Eye , seven-year-old Mia Sandoval shares her experience ... a memory care community in Los Angeles. The feel-good video ...
(Date:7/29/2014)... 29, 2014 According to a new ... leading global authority in medical device market research, the ... to over $8 billion by 2018. This growth ... the transcatheter heart valve market, which is comprised of ... transcatheter mitral valve repair (TMVR) segments. , There are ...
(Date:7/29/2014)... 29, 2014 According to the New ... the recreational and the medicinal sectors is mirroring the ... becomes more accepted in mainstream culture, many are turning ... the traditional and more dangerous forms of smoking the ... quite the trend in legalized states such as Colorado ...
(Date:7/29/2014)... 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... to improve access to essential pain medications for people ... ACS, Treat the Pain initiative, this new partnership will ... HIV/AIDS services throughout the country. , Swaziland has ... than 26 percent of adults ages 15-49 infected. Many ...
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:OZ Naturals to Launch Its Products in the UK 2
... planned strategic growth that ... Lansing and Michigan, LANSING, Mich., Oct. 8 In ... Grand River, accommodate up to 500 new jobs for,Lansing and ... subsidiary Accident Fund Insurance Company of America announced,today it will ...
... MURRYSVILLE, Pa., Oct. 8 Dixtal Medical, Inc.,and ... that Dixtal Medical,has acquired the Novametrix pulse oximetry ... will be marketed under the,Dixtal/Novametrix brand pursuant to ... Novametrix, founded in 1978 and acquired,by Respironics in ...
... mean more estrogen, bringing higher odds for the illness, researchers ... and shape of a woman,s hips may affect her daughter,s ... The study of 6,370 Finnish women found that breast cancer ... mothers with relatively wide hips, and nearly seven times higher ...
... Brothers is proud to be the,leading supplier of Official ... extends over 90 years. The embroidered badges and awards,produced ... substances. As a global manufacturer, Lion Brothers maintains ... substances in any of its,manufacturing processes. Lion tests materials ...
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce ... 25. During a conference call on October 25 at ... executives will,address inquiries from investors and analysts. Investors ... a live,webcast of the call at http://www.bms.com/ir ...
... or useless, the appendix now appears to have a reason ... bacteria living in the human gut. , Drawing upon a ... postulate that the beneficial bacteria in the appendix that aid ... evacuates the intestines and emerge afterwards to repopulate the gut. ...
Cached Medicine News:Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 2Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 3Health News:Woman's Hips Might Indicate Daughter's Breast Cancer Risk 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 3
... Drug Interaction Principles is the number one ... , An understanding of drug interactions has ... Since publication of the first edition of ... pharmacopoeia - coupled with prolonged human life ...
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Updated for 2006 with more than 800 complete drug entries, this mobile reference provides instant access to all the drug information nurses need in day-to-day practice....
... ACM-8 loads and unloads two centrifuges with ... via Cap Recognition the tube type is ... batches of three 5 position racks into ... single centrifuge ACM can be offered for ...
Medicine Products: